Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System

Ki Sun Jung, Yoo Jin Kim, Yeo Kyeoung Kim, Sung Kyu Park, Hoon Gu Kim, Soo Jeong Kim, Jinny Park, Chul Won Choi, Young Rok Do, Inho Kim, Seonyang Park, Yeung Chul Mun, Seong Hyun Jeong, Min Kyoung Kim, Hyeon Gyu Yi, Myung Hee Chang, Su Youn Kim, Je Hwan Lee, Jun Ho Jang

Research output: Contribution to journalArticle

Abstract

Introduction: Decitabine has shown clinical benefits in patients with intermediate (INT)-2 or high-risk myelodysplastic syndrome (MDS), determined according to the International Prognostic Scoring System (IPSS), but the benefits have not been well demonstrated in patients with lower-risk (IPSS low or INT-1) disease. Recently, it was proposed that the prognosis for patients with IPSS lower-risk disease is heterogeneous, with a substantial proportion of these patients having poor survival. Patients and Methods: This study included patients with IPSS lower-risk MDS from the DRAMA (An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome; NCT01400633) and DIVA (A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome; NCT01041846) studies, which were prospective observational studies on the efficacy and safety of decitabine treatment in patients with MDS. Using the Lower-Risk Prognostic Scoring System [LR-PSS], we classified IPSS lower-risk MDS. Patients in each LR-PSS category were divided according to overall response (OR) to decitabine treatment, and survival outcomes were compared. Results: One hundred sixteen patients were enrolled: LR-PSS category 1 (n = 12; 10.3%), category 2 (n = 56; 48.3%), and category 3 (n = 48; 41.4%). Survival outcomes differed among the 3 categories (P =.046). The overall survival according to OR showed a significant difference in total patients (P =.008) and category 3 patients (P =.003). We analyzed predictive factors for OR, but no variable was found to significantly affect OR. Conclusion: Decitabine treatment showed a survival benefit in the higher-risk group of IPSS lower-risk MDS patients who responded to treatment, and classification using the LR-PSS category was helpful for this subgroup, indicating that decitabine treatment might alter the natural course of disease in these patients.

Original languageEnglish
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

decitabine
Myelodysplastic Syndromes
Survival
Observational Studies

Keywords

  • Decitabine
  • IPSS
  • Lower-Risk Prognostic Scoring System
  • LR-PSS
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. / Jung, Ki Sun; Kim, Yoo Jin; Kim, Yeo Kyeoung; Park, Sung Kyu; Kim, Hoon Gu; Kim, Soo Jeong; Park, Jinny; Choi, Chul Won; Do, Young Rok; Kim, Inho; Park, Seonyang; Mun, Yeung Chul; Jeong, Seong Hyun; Kim, Min Kyoung; Yi, Hyeon Gyu; Chang, Myung Hee; Kim, Su Youn; Lee, Je Hwan; Jang, Jun Ho.

In: Clinical Lymphoma, Myeloma and Leukemia, 01.01.2019.

Research output: Contribution to journalArticle

Jung, KS, Kim, YJ, Kim, YK, Park, SK, Kim, HG, Kim, SJ, Park, J, Choi, CW, Do, YR, Kim, I, Park, S, Mun, YC, Jeong, SH, Kim, MK, Yi, HG, Chang, MH, Kim, SY, Lee, JH & Jang, JH 2019, 'Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System', Clinical Lymphoma, Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2019.06.003
Jung, Ki Sun ; Kim, Yoo Jin ; Kim, Yeo Kyeoung ; Park, Sung Kyu ; Kim, Hoon Gu ; Kim, Soo Jeong ; Park, Jinny ; Choi, Chul Won ; Do, Young Rok ; Kim, Inho ; Park, Seonyang ; Mun, Yeung Chul ; Jeong, Seong Hyun ; Kim, Min Kyoung ; Yi, Hyeon Gyu ; Chang, Myung Hee ; Kim, Su Youn ; Lee, Je Hwan ; Jang, Jun Ho. / Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. In: Clinical Lymphoma, Myeloma and Leukemia. 2019.
@article{cbfd9ce7e20e4765b212ec7f7d6fe5d6,
title = "Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System",
abstract = "Introduction: Decitabine has shown clinical benefits in patients with intermediate (INT)-2 or high-risk myelodysplastic syndrome (MDS), determined according to the International Prognostic Scoring System (IPSS), but the benefits have not been well demonstrated in patients with lower-risk (IPSS low or INT-1) disease. Recently, it was proposed that the prognosis for patients with IPSS lower-risk disease is heterogeneous, with a substantial proportion of these patients having poor survival. Patients and Methods: This study included patients with IPSS lower-risk MDS from the DRAMA (An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome; NCT01400633) and DIVA (A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome; NCT01041846) studies, which were prospective observational studies on the efficacy and safety of decitabine treatment in patients with MDS. Using the Lower-Risk Prognostic Scoring System [LR-PSS], we classified IPSS lower-risk MDS. Patients in each LR-PSS category were divided according to overall response (OR) to decitabine treatment, and survival outcomes were compared. Results: One hundred sixteen patients were enrolled: LR-PSS category 1 (n = 12; 10.3{\%}), category 2 (n = 56; 48.3{\%}), and category 3 (n = 48; 41.4{\%}). Survival outcomes differed among the 3 categories (P =.046). The overall survival according to OR showed a significant difference in total patients (P =.008) and category 3 patients (P =.003). We analyzed predictive factors for OR, but no variable was found to significantly affect OR. Conclusion: Decitabine treatment showed a survival benefit in the higher-risk group of IPSS lower-risk MDS patients who responded to treatment, and classification using the LR-PSS category was helpful for this subgroup, indicating that decitabine treatment might alter the natural course of disease in these patients.",
keywords = "Decitabine, IPSS, Lower-Risk Prognostic Scoring System, LR-PSS, Myelodysplastic syndrome",
author = "Jung, {Ki Sun} and Kim, {Yoo Jin} and Kim, {Yeo Kyeoung} and Park, {Sung Kyu} and Kim, {Hoon Gu} and Kim, {Soo Jeong} and Jinny Park and Choi, {Chul Won} and Do, {Young Rok} and Inho Kim and Seonyang Park and Mun, {Yeung Chul} and Jeong, {Seong Hyun} and Kim, {Min Kyoung} and Yi, {Hyeon Gyu} and Chang, {Myung Hee} and Kim, {Su Youn} and Lee, {Je Hwan} and Jang, {Jun Ho}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clml.2019.06.003",
language = "English",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",

}

TY - JOUR

T1 - Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System

AU - Jung, Ki Sun

AU - Kim, Yoo Jin

AU - Kim, Yeo Kyeoung

AU - Park, Sung Kyu

AU - Kim, Hoon Gu

AU - Kim, Soo Jeong

AU - Park, Jinny

AU - Choi, Chul Won

AU - Do, Young Rok

AU - Kim, Inho

AU - Park, Seonyang

AU - Mun, Yeung Chul

AU - Jeong, Seong Hyun

AU - Kim, Min Kyoung

AU - Yi, Hyeon Gyu

AU - Chang, Myung Hee

AU - Kim, Su Youn

AU - Lee, Je Hwan

AU - Jang, Jun Ho

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Decitabine has shown clinical benefits in patients with intermediate (INT)-2 or high-risk myelodysplastic syndrome (MDS), determined according to the International Prognostic Scoring System (IPSS), but the benefits have not been well demonstrated in patients with lower-risk (IPSS low or INT-1) disease. Recently, it was proposed that the prognosis for patients with IPSS lower-risk disease is heterogeneous, with a substantial proportion of these patients having poor survival. Patients and Methods: This study included patients with IPSS lower-risk MDS from the DRAMA (An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome; NCT01400633) and DIVA (A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome; NCT01041846) studies, which were prospective observational studies on the efficacy and safety of decitabine treatment in patients with MDS. Using the Lower-Risk Prognostic Scoring System [LR-PSS], we classified IPSS lower-risk MDS. Patients in each LR-PSS category were divided according to overall response (OR) to decitabine treatment, and survival outcomes were compared. Results: One hundred sixteen patients were enrolled: LR-PSS category 1 (n = 12; 10.3%), category 2 (n = 56; 48.3%), and category 3 (n = 48; 41.4%). Survival outcomes differed among the 3 categories (P =.046). The overall survival according to OR showed a significant difference in total patients (P =.008) and category 3 patients (P =.003). We analyzed predictive factors for OR, but no variable was found to significantly affect OR. Conclusion: Decitabine treatment showed a survival benefit in the higher-risk group of IPSS lower-risk MDS patients who responded to treatment, and classification using the LR-PSS category was helpful for this subgroup, indicating that decitabine treatment might alter the natural course of disease in these patients.

AB - Introduction: Decitabine has shown clinical benefits in patients with intermediate (INT)-2 or high-risk myelodysplastic syndrome (MDS), determined according to the International Prognostic Scoring System (IPSS), but the benefits have not been well demonstrated in patients with lower-risk (IPSS low or INT-1) disease. Recently, it was proposed that the prognosis for patients with IPSS lower-risk disease is heterogeneous, with a substantial proportion of these patients having poor survival. Patients and Methods: This study included patients with IPSS lower-risk MDS from the DRAMA (An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome; NCT01400633) and DIVA (A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome; NCT01041846) studies, which were prospective observational studies on the efficacy and safety of decitabine treatment in patients with MDS. Using the Lower-Risk Prognostic Scoring System [LR-PSS], we classified IPSS lower-risk MDS. Patients in each LR-PSS category were divided according to overall response (OR) to decitabine treatment, and survival outcomes were compared. Results: One hundred sixteen patients were enrolled: LR-PSS category 1 (n = 12; 10.3%), category 2 (n = 56; 48.3%), and category 3 (n = 48; 41.4%). Survival outcomes differed among the 3 categories (P =.046). The overall survival according to OR showed a significant difference in total patients (P =.008) and category 3 patients (P =.003). We analyzed predictive factors for OR, but no variable was found to significantly affect OR. Conclusion: Decitabine treatment showed a survival benefit in the higher-risk group of IPSS lower-risk MDS patients who responded to treatment, and classification using the LR-PSS category was helpful for this subgroup, indicating that decitabine treatment might alter the natural course of disease in these patients.

KW - Decitabine

KW - IPSS

KW - Lower-Risk Prognostic Scoring System

KW - LR-PSS

KW - Myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=85069820918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069820918&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2019.06.003

DO - 10.1016/j.clml.2019.06.003

M3 - Article

AN - SCOPUS:85069820918

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

ER -